Letter to the Editor
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 28, 2025; 31(4): 99312
Published online Jan 28, 2025. doi: 10.3748/wjg.v31.i4.99312
Elafibranor, a dual PPARα and PPARδ agonist, reduces alcohol-associated liver disease: Lessons from a mouse model
Luciano Pirola
Luciano Pirola, Carmen Laboratory, INSERM Unit 1060-Lyon 1 University, Pierre Benite 69310, France
Author contributions: Pirola L conceived and wrote the manuscript.
Conflict-of-interest statement: The author declares no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Luciano Pirola, PhD, Researcher, Carmen Laboratory, INSERM Unit 1060-Lyon 1 University, CENS ELI-2D Building, 165 Chemin du Grand Revoyet, Pierre Benite 69310, France. luciano.pirola@univ-lyon1.fr
Received: July 19, 2024
Revised: November 13, 2024
Accepted: November 20, 2024
Published online: January 28, 2025
Processing time: 163 Days and 21.8 Hours
Core Tip

Core Tip: Metabolic dysfunction-associated steatotic liver disease needs novel pharmacological treatments. Elafibranor, a PPAR agonist, remains a promising molecule against steatotic liver disease caused by alcohol consumption. Koizumi et al reported, in World Journal of Gastroenterology, on their use of a mouse model of alcohol-associated liver disease which indicated that hepatic steatosis, liver fibrosis, and hepatocyte apoptosis were alleviated by administration of elafibranor. These data support the potential beneficial action of elafibranor, warranting clinical testing.